logo
episode-header-image
Jul 2012
28m 32s

Barriers to Prescribing Crizotinib Follo...

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
About this episode
by Robert S. Miller, MD. Dr. Nathan Pennell discusses some of the interesting obstacles he encountered when trying to prescribe crizotinib for 3 patients with ALK positive non-small cell lung cancer in the first few weeks following FDA approval in 2011. 
Up next
Aug 2019
The Opaque Results of Federal Price Transparency Rules and State-Based Alternatives
Dr. Pennell and Dr. Kircher discuss the push for increased price transparency among stakeholders in an effort to control the rising costs of healthcare. Read the related article on ascopubs.org.   TRANSCRIPT: Welcome to the latest Journal of Oncology Practice podcast, brought to ... Show More
19m 24s
Jun 2019
Oncologists’ Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology Workforce
Dr. Nathan Pennell and Dr. Jennifer Ligibel discuss weight management and physical activity programs for patients with cancer. TRANSCRIPT: Hello, and welcome to the ASCO Journal of Oncology Practice podcast. This is Dr. Nate Pennell, medical oncologist at the Cleveland Clinic and ... Show More
18m 21s
Jun 2019
Potentially avoidable hospital readmissions in patients with advanced cancer
Dr. Pennell talks with Dr. Patrick Conner Johnson, hematology oncology fellow at the Dana Farber Cancer Institute Massachusetts General Hospital fellowship program about his and his co-authors' new study titled "Potentially avoidable hospital readmissions in patients with advance ... Show More
13m 3s
Recommended Episodes
Dec 2022
Declining ALS Patients Are Waiting On The FDA's Next Move
For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More
25m 57s
Jan 2014
E-cigs; PPI feedback; Be assertive with your doctor; Prostate cancer diagnosis
As the government calls for a ban on the sale of e cigarettes to under 18s, Dr Mark Porter is joined by Martin McKee, Gerard Hastings and Robert West to discuss who is using them and how they are being advertised. The chairman of NICE, David Haslam has suggested patients should d ... Show More
28m 3s
Oct 2023
Improving Early Recognition of Treatment-Responsive Causes of RPD
Dr. Jeff Ratliff talks with Dr. Gregg Day about the adaption of the STAM3P screening scores in clinical practice to minimize diagnosis delays and missed opportunities for treatment in patients with suspected rapidly progressive dementia. Read the related article in Annals of Neur ... Show More
16m 31s
May 2022
Patient-Reported Outcomes in Clinical Trials
JAMA Associate Editor Ethan Basch, MD, and Melanie Calvert, PhD, from the University of Birmingham, UK, discuss barriers to and strategies for including rigorous patient-reported outcomes in clinical trials, and reflect on Dr Calvert’s recent JAMA paper on related ethical implica ... Show More
14m 26s
Oct 2017
Oct 6 Cardiology News
Stopping aspirin, TAVR durability, meditation, triathlon risk, and BP control in low-income patients are discussed by Dr Mandrola in this week's podcast. 
11m 46s
Jun 2020
Neurology: Gepants - Ubrogepant and Rimegepant
Dr. Tesha Monteith discusses the FDA approval of the first gepants of its class: ubrogepant and rimegepant. 
2m 36s
Apr 2021
Old Drugs, New Disease
As medical professionals search for new treatments to help Covid-19 patients, some researchers are taking a second look at drugs that have already been approved by the FDA. CNN Chief Medical Correspondent Dr. Sanjay Gupta talks to Dr. David Fajgenbaum about repurposing old drugs ... Show More
11m 31s
Jul 2023
Keeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
Host: Harry Paul Erba, MD, PhD Guest: Courtney DiNardo, MD Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss ... Show More
23m 30s
Oct 2023
#341: What NOT to say to FDA
Description:Dive into the enlightening world of FDA inspections with Etienne Nichols and Mike Drues. In this comprehensive episode, the duo decodes the essence of effective communication, the importance of managing expectations, and the art of proactive dialogue with the FDA. The ... Show More
49m 11s